Long-acting Pramlintide

ASX
LCT 0.041   Last updated EOD 10th December 2018
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Long-acting Pramlintide

Target: Obesity

 

Obesity is a risk factor for many health conditions such as diabetes, cardiovascular disease, osteoarthritis and cancer. Two million New Zealanders will be obese in 20 years’ time according to a report from the University of Otago published in the Australian and New Zealand Journal of Public Health in July. In 2014 more than 600 million adults worldwide were obese. In 2016 FDA-approved obesity medication sales were US$455 million, predicted to reach US$2.9 billion in 2021.

 

Pramlintide is an FDA-approved peptide drug that mimics the actions of a natural hormone, amylin, to control blood glucose. It is approved for type 1 and type 2 diabetes in conjunction with insulin. Pramlintide also reduces caloric intake, resulting in weight loss. This means it could be a valuable tool for mitigating one of the biggest risk factors for prediabetes/diabetes – obesity. Pramlintide in its current format has limitations chiefly it is short-acting so needs to be administered (by injection) several times a day.

 

Professor Debbie Hay is the lead investigator for weight loss pilot studies in animals now underway at the University of Auckland using a pramlintide slow release compound synthesised at the university.

 

If this compound meets the efficacy endpoints we intend to initiate Phase I clinical studies to demonstrate long-term pharmacokinetics. If successful, this compound would be an attractive out licence candidate to treat morbid obesity.

 

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.